Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2014 2
2015 1
2021 4
2022 5
2023 1
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.
Herrmann A, Gege C, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, Ip WH, Weil T, Hunszinger V, Groß R, Heinen N, Pfaender S, Reuter S, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Grunwald T, Hietel B, Cynis H, Münch J, Sparrer KMJ, Ensser A, Tenbusch M, Dobner T, Vitt D, Kohlhof H, Hahn F. Herrmann A, et al. Among authors: uhlig n. Antiviral Res. 2024 Nov;231:106008. doi: 10.1016/j.antiviral.2024.106008. Epub 2024 Sep 19. Antiviral Res. 2024. PMID: 39306285 Free article.
Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapy.
Mertlitz S, Riesner K, Kalupa M, Uhlig N, Cordes S, Verlaat L, Jamali M, Li N, Mohamed HMER, Bullinger L, Moss S, Greenwood J, Jatzlau J, Knaus P, Vallecillo-Garcia P, Penack O. Mertlitz S, et al. Among authors: uhlig n. J Immunother Cancer. 2025 Mar 21;13(3):e009372. doi: 10.1136/jitc-2024-009372. J Immunother Cancer. 2025. PMID: 40118496 Free PMC article.
Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2.
Groß R, Dias Loiola LM, Issmail L, Uhlig N, Eberlein V, Conzelmann C, Olari LR, Rauch L, Lawrenz J, Weil T, Müller JA, Cardoso MB, Gilg A, Larsson O, Höglund U, Pålsson SA, Tvilum AS, Løvschall KB, Kristensen MM, Spetz AL, Hontonnou F, Galloux M, Grunwald T, Zelikin AN, Münch J. Groß R, et al. Among authors: uhlig n. Adv Sci (Weinh). 2022 Jul;9(20):e2201378. doi: 10.1002/advs.202201378. Epub 2022 May 11. Adv Sci (Weinh). 2022. PMID: 35543527 Free PMC article.
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.
Lapuente D, Fuchs J, Willar J, Vieira Antão A, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M. Lapuente D, et al. Among authors: uhlig n. Nat Commun. 2021 Nov 26;12(1):6871. doi: 10.1038/s41467-021-27063-4. Nat Commun. 2021. PMID: 34836955 Free PMC article.
Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses.
Weil T, Kirupakaran A, Le MH, Rebmann P, Mieres-Perez J, Issmail L, Conzelmann C, Müller JA, Rauch L, Gilg A, Wettstein L, Groß R, Read C, Bergner T, Pålsson SA, Uhlig N, Eberlein V, Wöll H, Klärner FG, Stenger S, Kümmerer BM, Streeck H, Fois G, Frick M, Braubach P, Spetz AL, Grunwald T, Shorter J, Sanchez-Garcia E, Schrader T, Münch J. Weil T, et al. Among authors: uhlig n. JACS Au. 2022 Sep 6;2(9):2187-2202. doi: 10.1021/jacsau.2c00220. eCollection 2022 Sep 26. JACS Au. 2022. PMID: 36186568 Free PMC article.
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, Pfaender S, Balkema-Buschmann A, Dobbelstein M. Stegmann KM, et al. Among authors: uhlig n. iScience. 2022 May 20;25(5):104293. doi: 10.1016/j.isci.2022.104293. Epub 2022 Apr 25. iScience. 2022. PMID: 35492218 Free PMC article.
Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.
Reus P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, Nordling-David MM, Jbara-Agbaria D, Ciesek S, Bojkova D, Cinatl J, Burger-Kentischer A, Rupp S, Zaliani A, Grunwald T, Gribbon P, Kannt A, Golomb G. Reus P, et al. Among authors: uhlig n. J Control Release. 2023 Dec;364:654-671. doi: 10.1016/j.jconrel.2023.10.050. Epub 2023 Nov 16. J Control Release. 2023. PMID: 37939853 Free article.
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.
Peter AS, Roth E, Schulz SR, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-Schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Grüner E, Peterhoff D, Ciesek S, Hoffmann M, Pöhlmann S, McKay PF, Shattock RJ, Wölfel R, Socher E, Wagner R, Eichler J, Sticht H, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler TH, Grunwald T, Überla K, Jäck HM. Peter AS, et al. Among authors: uhlig n. Eur J Immunol. 2022 May;52(5):770-783. doi: 10.1002/eji.202149374. Epub 2021 Sep 13. Eur J Immunol. 2022. PMID: 34355795 Free PMC article.
20 results